安羅替尼聯(lián)合PD-1抑制劑治療晚期卵巢癌臨床轉(zhuǎn)歸的影響因素及其預(yù)測效能
打開文本圖片集
[關(guān)鍵詞]卵巢腫瘤；程序性細(xì)胞死亡受體1;安羅替尼；治療結(jié)果;影響因素分析[中圖分類號] R737.31；R392.1 ［文獻(xiàn)標(biāo)志碼］A [文章編號] 2096-5532（2025）03-0406-05doi：10.11712/jms.2096-5532.2025.61.091 [開放科學(xué)（資源服務(wù)）標(biāo)識碼（OSID）][網(wǎng)絡(luò)出版] https：//link.cnki.net/urlid/37.1517.R.20250724.1407.001; 2025-07-2417：18：18
Influencingfactorsfortreatmentoutcomeofanlotinibcombined withPD-1inibitors inadvanced epithelialovariancancerandtheir predictive eficacyGETan，SHEN Jian，ZHAORong（Pharmacy Departmentof Ruijin Hospital，Shanghai Jiaotong University School of Medicine，Shanghai 20o025，China）
[Abstract]ObjectiveTo investigate thefactors influencing the clinicaloutcomeof anlotinib combined with programmed death-1（PD-1）inibitors treatingadvancedepithelialovariancancer（EOC）andtheirpredictiveeficacy.MethodsWedivided 157 patientswithadvancedEOCtreatedwithanlotinibcombinedwithPD-1inhibitorsinourhospitalfromAugust202OtoAugust 2023intogoodoutcome groupand pooroutcomegroup.Basedonthepatients’clinicaland biochemical data，thefactorsaffecting clinicaloutcome wereanalyzed，andtheirpredictiveeficacywasaessed.ResultsHighgradeserouscarcioma，aphsicalsta tus（PS） score of 2 points，PD-Ll expression ≥1% ，highcarbohydrate antigen 125（CA125）levels，and high human epididymis protein 4（HE4） levels were independent risk factors for the clinical outcome of advanced EOC（ OR=1.730-2.109，P<0.05 ） Combining pathologicaltype，PSscore，PD-L1，CAl25，andHE4forclinicaloutcomeprediction，theareaunderthereceiverope rating characteristic curve was O.873，with a sensitivity of 95.65% and a specificity of 70.00% . ConclusionPathological type， PD-L1，CA125，HE4，andPSscoreareindependentfactorinfluencingtheclinicaloutcomeofanlotinibplusPD-1inibitors treating advanced EOC，which demonstrate high predictive efficacy when combined.
[Key words]ovarian neoplasms；programmed celldeath 1receptor；anlotinib；treatment outcome;root cause analysis
上皮性卵巢癌（EOC）為女性常見的惡性腫瘤，多起源于卵巢表面上皮細(xì)胞，可分為高級別漿液性癌、子宮內(nèi)膜樣癌、透明細(xì)胞癌和黏液性癌等，其中高級別漿液性癌最為常見[1]。（剩余7457字）